Kairos Pharma Files 8-K Report

Ticker: KAPA · Form: 8-K · Filed: Oct 10, 2024 · CIK: 1962011

Sentiment: neutral

Topics: sec-filing, 8-k, regulatory

TL;DR

Kairos Pharma filed an 8-K. Check for updates.

AI Summary

On October 9, 2024, Kairos Pharma, Ltd. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific financial figures or material events beyond the filing itself were detailed in the provided text.

Why It Matters

This filing indicates that Kairos Pharma, Ltd. is making a regulatory submission to the SEC, which could contain important updates for investors.

Risk Assessment

Risk Level: low — The provided text is a standard SEC filing notification and does not contain information about specific risks or material events.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Kairos Pharma, Ltd.?

The filing is primarily for "Other Events" and "Financial Statements and Exhibits" as per the provided text.

What is the date of the earliest event reported in this filing?

The date of the earliest event reported is October 9, 2024.

What is the principal executive office address for Kairos Pharma, Ltd.?

The address is 2355 Westwood Blvd. , #139 Los Angeles CA 90064.

What is the SIC code for Kairos Pharma, Ltd.?

The Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.

What is the state of incorporation for Kairos Pharma, Ltd.?

Kairos Pharma, Ltd. is incorporated in Delaware.

Filing Stats: 914 words · 4 min read · ~3 pages · Grade level 11 · Accepted 2024-10-10 17:30:24

Key Financial Figures

Filing Documents

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2024 Kairos Pharma, Ltd. (Exact name of registrant as specified in its charter) Delaware 001-42275 46-2993314 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 2355 Westwood Blvd. , #139 Los Angeles CA 90064 (Address of principal executive offices) (Zip Code) (310) 948-2356 Registrant's telephone number, including area code N/A (Former name or former address, if changed from last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol (s) Name of each exchange on which registered Common Stock, par value $0.001, per share KAPA The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 8.01 Other Information. On October 9, 2024, Kairos Pharma Ltd., a Delaware corporation (the "Company"), issued a press release announcing that the Company's Chief Executive Officer, Dr. John S. Yu, M.D., will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit (the "2024 Maxim Healthcare Virtual Summit") where he will be speaking with Jason McCarthy, Ph.D., Senior Managing Director, Head of Biotechnology Research at Maxim Group. The 2024 Maxim Healthcare Virtual Summit is being held virtually from October 15 to 17, 2024, and can be accessed by visiting https://m-vest.com/events/healthcare-10152024 . On October 10, 2024, the Company updated its corporate presentation that it intends to use at the 2024 Maxim Healthcare Virtual Summit (the "Investor Deck") and posted it on its website at www.kairospharma.com. A copy of the Investor Deck is attached as Exhibit 99.1 and incorporated herein by reference. The information included in this Item 8.01, including Exhibit 99.1, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to liabilities under that section, and shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act or the Exchange Act, regardless of any general incorporation language in such filings. This Current Report on Form 8-K will not be deemed an admission as to the materiality of any information of the information contained in this Item 8.01, including Exhibit 99.1. Forward-Looking This Current Report on Form 8-K contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Forward-looking statements may relate to statements concerning future results, strategy and plans of the Company (including certain statements which may be identified by the use of the words "plans," "expects," "does not expect," "estimated," "is expected," "budget," "scheduled," "estimates," "forecasts," "intends," "anticipates," "does not anticipate" or "believes," or variations of such words and phrases, or state that certain actions, events or results "may," "could," "would," "might," "projects," "will," "will be taken," "occur" or "be achieved"). Forward-looking statements are based on the opinions and estimates of management of the Company, as of the date such statements are made, and they are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. Additional information on these and other factors that may cause actual results and the Company's performance to differ materially is included in the Company's

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing